Europe PMC

Background/Objectives: Psoriasis is a chronic inflammatory skin disease increasingly linked to psychiatric and behavioral comorbidities, including depression, anxiety, and substance use disorders. Shared inflammatory pathways, including elevated IL-6, TNF-α, and IL-17, may link psoriasis with psychiatric disorders such as depression and anxiety. The bidirectional interaction between systemic inflammation and mental health may exacerbate the disease burden and affect treatment outcomes. The objec

Psoriasis is a chronic immune-mediated skin disease that is increasingly understood as a systemic inflammatory condition with implications that extend far beyond the skin. Among its most serious associations is an elevated risk of cardiovascular disease, which has emerged as a leading cause of morbidity and mortality in affected patients. The persistent immune activation characteristic of psoriasis, driven by cytokines such as tumor necrosis factor α (TNFα), interleukin (IL)-17, and IL-23, contr

Background: Psoriasis is a chronic autoimmune condition characterized by recurrent episodes of skin inflammation. Despite progress in treatment, managing flare-ups of psoriasis remains a significant hurdle once the therapy is halted. This review aims to unravel the enigma of relapse by examining the interactions between epigenetics, metabolic reprogramming, and inflammatory memory.Methods and Results: Skin-resident memory T cells and keratinocytes with a history of inflammation play crucial role

Psoriasis is a chronic autoimmune disease of the skin manifested by keratinocyte hyperproliferation, immune dysregulation, and chronic inflammation that result in scaly plaques. Conventional interventions such as corticosteroids, immunosuppressants, and biologics offer symptomatic relief but are limited by side effects and incomplete remission. Psoriasis pathogenesis is complex and entails numerous immune cells (dendritic cells, Th1, Th17, Th22, Tregs, macrophages, NK cells) and molecular pathwa

Objective.— To analyze a published study on all-cause mortality between psoriatic arthritis and matched population comparator-subjects to derive comparative mortality statistics applicable to life insurance underwriting.Method.— The pixel method was employed for extracting cumulative survivals. It was chosen for its capability to extract data from published graphs despite potential precision and reliability limitations.Results.— The mortality analysis indicated an increase in mortality starting

Objectives Little is known about the ideal service delivery model and shortcomings in patient experiences in the NHS for patients with psoriatic arthritis (PsA). The objective of this work was to identify unmet needs perceived within the current health service delivery model for PsA from the UK Psoriatic Arthritis Priority Setting Partnership (PsA-PSP).Methods An online survey was conducted in 2020 and distributed to people with PsA, their carers and clinicians to identify research priorities in

No abstract supplied.Weiterlesen

Introduction Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients' quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and biologic therapies in the region. This observational cohort study provides a comprehensive analysis of baseline disease characteristics, comorbidities, and treatment efficacy among patients enrolled in PSORSA, with an emphasis on risankizumab.Methods Da

Introduction Bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has shown high efficacy in clinical trials. However, real-world data on its use in psoriatic arthritis (PsA) are limited. This study aimed to evaluate the effectiveness and safety of BKZ over 24 weeks in a real-world setting.Methods A retrospective, multicenter study was conducted at two Italian rheumatology centers, enrolling adult patients with PsA who initiated BKZ treatment between January 2023 a

Introduction The International Psoriasis Council (IPC) reclassified patients eligible for systemic therapy to include those with body surface area (BSA) > 10%, psoriasis lesions in high-impact areas, or failure of topical therapy. Risankizumab is an interleukin-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. This retrospective study evaluated the real-world effectiveness of risankizumab in patients with BSA 3-10% and patients meeting IPC systemic therapy criter

Psoriasis is a chronic inflammatory autoimmune skin disease with enhanced skin cell turnover. Despite the therapies currently available, better and target-oriented therapies are needed. Fisetin is a flavonoid with antioxidant, anti-inflammatory, and immunomodulatory properties. It shows therapeutic potential, but its poor bioavailability and penetration into the skin cannot be used effectively to treat psoriasis. While fisetin-loaded nanoformulations in cancer and other diseases have been explor

Objective This study aims to investigate the relationship between Relative Fat Mass (RFM) and the risk of psoriasis based on data from the US National Health and Nutrition Examination Survey (NHANES) from 2009 to 2014.Methods This cross-sectional study included 19,565 adults aged 20 years and older. Psoriasis diagnosis was determined using self-reported questionnaires, and RFM was calculated based on established formulas. Multivariable logistic regression models were used to analyze the associat

Unlabelled This study analyzed over 2000 images of psoriasis across major web-based platforms and found a significant underrepresentation of darker skin tones, highlighting a critical gap in dermatologic representation that may contribute to misdiagnoses and health disparities among patients with skin of color.Weiterlesen

No abstract supplied.Weiterlesen

Objective Residual confounding effects and disease severity are attributed to controversial results in studies of psoriatic disease (PsD) and mortality. We aimed to evaluate the risk of mortality in patients with incident PsD, compared to matched controls from the population.Methods We used the nationwide, population-based insurance claim datasets in Taiwan from 2010 to 2018. Incident cases of PsD were identified by International Classification of Diseases (ICD) codes. A nonexposed cohort was es

Psoriasis is a chronic inflammatory skin disease with a high world-wide incidence. Rutin, a natural citrus flavonoid glycoside, has been shown to have anti-inflammatory and antioxidant properties. To investigate the protective effects of rutin in imiquimod (IMQ)-induced psoriasis model mice and its underlying molecular mechanism. IMQ was applied to mice to induce inflammatory skin that phenotypically mimics psoriasis. The Psoriasis Area Severity Index (PASI) score was used to evaluate the degree

The Psoriasis Area and Severity Index (PASI) is widely used to evaluate psoriatic disease activity in clinical settings; however, its limitations hinder its practicality in routine use. The Simple-Measure for Assessing Psoriasis Severity (S-MAPA) has emerged as a promising tool addressing these limitations, providing a more feasible approach for assessing disease severity. This study aimed to evaluate the S-MAPA as a sensitive and practical alternative to existing instruments for measuring psori

Aim Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.Methods LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index

Psoriasis, a chronic skin autoimmune disease characterized by abnormal immune responses, is influenced by genetic and environmental factors. Recent microbiota research has revealed that short-chain fatty acids (SCFAs), metabolites produced by gut microbiota, play a pivotal role in regulating immune function and inflammation. This review examines the current literature on the relationship between gut dysbiosis, SCFA production, and immune modulation in psoriasis, focusing on emerging evidence fro

Moderate to severe psoriasis has been reported as an independent risk factor for IgA nephropathy (IgAN). IgAN is characterized by episodic microscopic hematuria, which can progress to end-stage renal disease (ESRD). Managing therapeutic interventions for psoriasis patients requiring dialysis due to ESRD presents significant challenges. We present a case of severe plaque psoriasis in a patient concurrently diagnosed with IgAN who is dependent on hemodialysis. Over the past two months, his conditi

Background Psoriasis is a chronic inflammatory skin condition driven by immune dysregulation, significantly diminishing patients' quality of life. The advent of targeted biological therapies and small molecule inhibitors has transformed the treatment landscape for moderate-to-severe Psoriasis. Nevertheless, there remains a scarcity of comparative efficacy and safety data between these therapeutic classes, highlighting the need for a systematic review to evaluate their relative performance.Object

No abstract supplied.Weiterlesen

Introduction SB17 is a ustekinumab (UST) biosimilar targeting interleukin-12/23 for treating immune-mediated inflammatory diseases (IMIDs). The development of UST biosimilars like SB17 may help address the high cost of innovator biologics, offering affordable alternatives without compromising efficacy or safety.Areas covered This review encompasses the totality of evidence supporting SB17's similarity to UST, its regulatory approval, and indication extrapolation. It also discusses SB17's lower i

Background/objectives Guttate psoriasis onset and plaque psoriasis flares are associated with streptococcal pharyngitis. Literature regarding the relationship between anogenital bacterial dermatitis and psoriasis in pediatric patients is limited. We aimed to evaluate the clinical characteristics, microbiology, and treatment course of patients with psoriasis/psoriasiform dermatitis and concomitant pharyngeal and/or anogenital bacterial infections.Methods A multicenter retrospective review of pati

Background The approach to pediatric psoriasis requires special considerations, given the potential for negative consequences on overall physical and psychosocial health.Objective The aim of this study was to systematically review the literature to characterize the burden of pediatric psoriasis.Methods Papers assessing associations between pediatric psoriasis (in children <18 years old) and quality of life, physical symptoms (e.g., skin pain, itch, sleep disruption), and adverse psychological